{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:25:47Z","timestamp":1789244747132,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province of China","doi-asserted-by":"crossref","award":["24JRRA323"],"award-info":[{"award-number":["24JRRA323"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gansu Province Young Science and Technology Talents Support Project Program","award":["GXH20210611"],"award-info":[{"award-number":["GXH20210611"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82060551"],"award-info":[{"award-number":["82060551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gansu Province Health Care Industry Research Program Projects","award":["GSWSKY2020-11"],"award-info":[{"award-number":["GSWSKY2020-11"]}]},{"DOI":"10.13039\/501100007764","name":"Lanzhou Science and Technology Bureau","doi-asserted-by":"crossref","award":["2019-4-43"],"award-info":[{"award-number":["2019-4-43"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81392-0","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T04:31:04Z","timestamp":1732854664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6"],"prefix":"10.1038","volume":"14","author":[{"given":"Mingzhen","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoshui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongfei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningzu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"81392_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley, P. J. et al. Cholangiocarcinoma. Nat. Reviews Disease Primers 7, 65. https:\/\/doi.org\/10.1038\/s41572-021-00300-2 (2021).","journal-title":"Nat. Reviews Disease Primers"},{"key":"81392_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17, 557\u2013588. https:\/\/doi.org\/10.1038\/s41575-020-0310-z (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"81392_CR3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","volume":"245","author":"ML DeOliveira","year":"2007","unstructured":"DeOliveira, M. L. et al. Cholangiocarcinoma - Thirty-one-year experience with 564 patients at a single institution. Ann. Surg. 245, 755\u2013762. https:\/\/doi.org\/10.1097\/01.sla.0000251366.62632.d3 (2007).","journal-title":"Ann. Surg."},{"key":"81392_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/13543784.2021.1880564","volume":"30","author":"M Cadamuro","year":"2021","unstructured":"Cadamuro, M. et al. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opin. Investig. Drugs. 30, 377\u2013388. https:\/\/doi.org\/10.1080\/13543784.2021.1880564 (2021).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"81392_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/bjs.10452","volume":"104","author":"K Komaya","year":"2017","unstructured":"Komaya, K. et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br. J. Surg. 104, 426\u2013433. https:\/\/doi.org\/10.1002\/bjs.10452 (2017).","journal-title":"Br. J. Surg."},{"key":"81392_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.hpb.2017.10.016","volume":"20","author":"L Courtin-Tanguy","year":"2018","unstructured":"Courtin-Tanguy, L. et al. Multicentre study of the impact of factors that may affect long-term survival following pancreaticoduodenectomy for distal cholangiocarcinoma. Hpb 20, 405\u2013410. https:\/\/doi.org\/10.1016\/j.hpb.2017.10.016 (2018).","journal-title":"Hpb"},{"key":"81392_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.radonc.2020.03.017","volume":"147","author":"WW Zhou","year":"2020","unstructured":"Zhou, W. W. et al. Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma. Radiother Oncol. 147, 111\u2013117. https:\/\/doi.org\/10.1016\/j.radonc.2020.03.017 (2020).","journal-title":"Radiother Oncol."},{"key":"81392_CR8","doi-asserted-by":"publisher","first-page":"891652","DOI":"10.3389\/fonc.2022.891652","volume":"12","author":"TB Emran","year":"2022","unstructured":"Emran, T. B. et al. Multidrug Resistance in Cancer: understanding Molecular mechanisms, Immunoprevention and therapeutic approaches. Front. Oncol. 12, 891652. https:\/\/doi.org\/10.3389\/fonc.2022.891652 (2022).","journal-title":"Front. Oncol."},{"key":"81392_CR9","doi-asserted-by":"crossref","unstructured":"Zheng, Q. F., Zhang, B., Li, C. F. & Zhang, X. W. Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models. Frontiers in Oncology 12. https:\/\/doi.org\/ARTN 85073210.3389\/fonc.850732 (2022). (2022).","DOI":"10.3389\/fonc.2022.850732"},{"key":"81392_CR10","doi-asserted-by":"publisher","unstructured":"Khosla, D. et al. Recent advances in Molecular Pathobiology and therapeutic approaches. Cancers (Basel). 16. https:\/\/doi.org\/10.3390\/cancers16040801 (2024). Cholangiocarcinoma.","DOI":"10.3390\/cancers16040801"},{"key":"81392_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4251\/wjgo.v5.i7.171","volume":"5","author":"N Ramirez-Merino","year":"2013","unstructured":"Ramirez-Merino, N., Aix, S. P. & Cortes-Funes, H. Chemotherapy for cholangiocarcinoma: an update. World J. Gastrointest. Oncol. 5, 171\u2013176. https:\/\/doi.org\/10.4251\/wjgo.v5.i7.171 (2013).","journal-title":"World J. Gastrointest. Oncol."},{"key":"81392_CR12","doi-asserted-by":"crossref","unstructured":"Qin, H. J., Zheng, G., Li, Q. & Shen, L. Y. Metabolic reprogramming induced by DCA enhances cisplatin sensitivity through increasing mitochondrial oxidative stress in cholangiocarcinoma. Front Pharmacol 14. https:\/\/doi.org\/ARTN 112831210.3389\/fphar.1128312 (2023). (2023).","DOI":"10.3389\/fphar.2023.1128312"},{"key":"81392_CR13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ar.20710","volume":"291","author":"T Roskams","year":"2008","unstructured":"Roskams, T. & Desmet, V. Embryology of extra- and intrahepatic bile ducts, the ductal plate. Anat. Rec. 291, 628\u2013635. https:\/\/doi.org\/10.1002\/ar.20710 (2008).","journal-title":"Anat. Rec"},{"key":"81392_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12957-022-02510-8","volume":"20","author":"X Hou","year":"2022","unstructured":"Hou, X. et al. Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells. World J. Surg. Oncol. 20, 37. https:\/\/doi.org\/10.1186\/s12957-022-02510-8 (2022).","journal-title":"World J. Surg. Oncol."},{"key":"81392_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1126\/science.346.6205.28","volume":"346","author":"J Couzin-Frankel","year":"2014","unstructured":"Couzin-Frankel, J. Hope in a mouse. Science 346, 28\u201329. https:\/\/doi.org\/10.1126\/science.346.6205.28 (2014).","journal-title":"Science"},{"key":"81392_CR16","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1126\/science.aaw6985","volume":"364","author":"D Tuveson","year":"2019","unstructured":"Tuveson, D. & Clevers, H. Cancer modeling meets human organoid technology. Science 364, 952\u2013955. https:\/\/doi.org\/10.1126\/science.aaw6985 (2019).","journal-title":"Science"},{"key":"81392_CR17","doi-asserted-by":"publisher","first-page":"19909","DOI":"10.1038\/s41598-019-56356-4","volume":"9","author":"SY Kim","year":"2019","unstructured":"Kim, S. Y. et al. Patient-derived cells to Guide targeted therapy for Advanced Lung Adenocarcinoma. Sci. Rep. 9, 19909. https:\/\/doi.org\/10.1038\/s41598-019-56356-4 (2019).","journal-title":"Sci. Rep."},{"key":"81392_CR18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.7150\/jca.68264","volume":"13","author":"YH Li","year":"2022","unstructured":"Li, Y. H., Song, Y. H. & Liu, S. L. The new insight of treatment in Cholangiocarcinoma. J. Cancer. 13, 450\u2013464. https:\/\/doi.org\/10.7150\/jca.68264 (2022).","journal-title":"J. Cancer"},{"key":"81392_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.21037\/hbsn-23-215","volume":"12","author":"RIR Macias","year":"2023","unstructured":"Macias, R. I. R., Rimassa, L. & Lamarea, A. The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment. Hepatobil Surg. Nutr. 12, 457\u2013461. https:\/\/doi.org\/10.21037\/hbsn-23-215 (2023).","journal-title":"Hepatobil Surg. Nutr."},{"key":"81392_CR20","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.Cd-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul, A. et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of Cholangiocarcinoma. Cancer Discov. 7, 1116\u20131135. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0368 (2017).","journal-title":"Cancer Discov."},{"key":"81392_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","volume":"73","author":"R Montal","year":"2020","unstructured":"Montal, R. et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J. Hepatol. 73, 315\u2013327. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.008 (2020).","journal-title":"J. Hepatol."},{"key":"81392_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/hep.32624","volume":"77","author":"MJ Deng","year":"2023","unstructured":"Deng, M. J. et al. Proteogenomic characterization of cholangiocarcinoma. Hepatology 77, 411\u2013429. https:\/\/doi.org\/10.1002\/hep.32624 (2023).","journal-title":"Hepatology"},{"key":"81392_CR23","doi-asserted-by":"publisher","first-page":"638360","DOI":"10.3389\/fonc.2021.638360","volume":"11","author":"V Merz","year":"2021","unstructured":"Merz, V. et al. Targeting KRAS: the Elephant in the room of epithelial cancers. Front. Oncol. 11, 638360. https:\/\/doi.org\/10.3389\/fonc.2021.638360 (2021).","journal-title":"Front. Oncol."},{"key":"81392_CR24","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/14728222.2021.2013801","volume":"25","author":"M Simbolo","year":"2021","unstructured":"Simbolo, M. et al. Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles. Expert Opin. Ther. Tar. 25, 1095\u20131105. https:\/\/doi.org\/10.1080\/14728222.2021.2013801 (2021).","journal-title":"Expert Opin. Ther. Tar"},{"key":"81392_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","volume":"39","author":"SV Ambudkar","year":"1999","unstructured":"Ambudkar, S. V. et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. 39, 361\u2013398. https:\/\/doi.org\/10.1146\/annurev.pharmtox.39.1.361 (1999).","journal-title":"Annu. Rev. Pharmacol."},{"key":"81392_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1158\/1535-7163.Mct-09-0663","volume":"9","author":"JS Lagas","year":"2010","unstructured":"Lagas, J. S. et al. Breast Cancer resistance protein and P-glycoprotein limit Sorafenib Brain Accumulation. Mol. Cancer Ther. 9, 319\u2013326. https:\/\/doi.org\/10.1158\/1535-7163.Mct-09-0663 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"81392_CR27","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.3748\/wjg.v11.i18.2748","volume":"11","author":"N Tepsiri","year":"2005","unstructured":"Tepsiri, N. et al. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J. Gastroentero. 11, 2748\u20132753. https:\/\/doi.org\/10.3748\/wjg.v11.i18.2748 (2005).","journal-title":"World J. Gastroentero"},{"key":"81392_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2011.10.024","volume":"316","author":"H Yoon","year":"2012","unstructured":"Yoon, H. et al. L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells. Cancer Lett. 316, 70\u201376. https:\/\/doi.org\/10.1016\/j.canlet.2011.10.024 (2012).","journal-title":"Cancer Lett."},{"key":"81392_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3727\/096504015X14424348426071","volume":"23","author":"W Seubwai","year":"2016","unstructured":"Seubwai, W. et al. Inhibition of NF-kappaB activity enhances sensitivity to anticancer drugs in Cholangiocarcinoma Cells. Oncol. Res. 23, 21\u201328. https:\/\/doi.org\/10.3727\/096504015X14424348426071 (2016).","journal-title":"Oncol. Res."},{"key":"81392_CR30","doi-asserted-by":"publisher","first-page":"e2400206","DOI":"10.1200\/PO.24.00206","volume":"8","author":"WA Preston","year":"2024","unstructured":"Preston, W. A. et al. Extrahepatic Cholangiocarcinoma: genomic variables Associated with Anatomic Location and Outcome. JCO Precis Oncol. 8, e2400206. https:\/\/doi.org\/10.1200\/PO.24.00206 (2024).","journal-title":"JCO Precis Oncol."},{"key":"81392_CR31","doi-asserted-by":"publisher","first-page":"e249840","DOI":"10.1001\/jamanetworkopen.2024.9840","volume":"7","author":"GT Moffat","year":"2024","unstructured":"Moffat, G. T. et al. KRAS allelic variants in biliary tract cancers. JAMA Netw. Open. 7, e249840. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.9840 (2024).","journal-title":"JAMA Netw. Open."},{"key":"81392_CR32","doi-asserted-by":"crossref","unstructured":"Khosla, D. et al. Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches. Cancers 16. https:\/\/doi.org\/ARTN 80110.3390\/cancers16040801 (2024).","DOI":"10.3390\/cancers16040801"},{"key":"81392_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fphar.2018.00006","volume":"9","author":"SA Langhans","year":"2018","unstructured":"Langhans, S. A. Three-Dimensional in Vitro Cell Culture models in Drug Discovery and Drug Repositioning. Front. Pharmacol. 9, 6. https:\/\/doi.org\/10.3389\/fphar.2018.00006 (2018).","journal-title":"Front. Pharmacol."},{"key":"81392_CR34","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.ajpath.2022.05.007","volume":"192","author":"A Isidan","year":"2022","unstructured":"Isidan, A. et al. Development and characterization of human primary Cholangiocarcinoma Cell lines. Am. J. Pathol. 192, 1200\u20131217. https:\/\/doi.org\/10.1016\/j.ajpath.2022.05.007 (2022).","journal-title":"Am. J. Pathol."},{"key":"81392_CR35","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1021\/mp300028a","volume":"9","author":"P Martinez-Becerra","year":"2012","unstructured":"Martinez-Becerra, P. et al. No correlation between the expression of FXR and genes involved in Multidrug Resistance phenotype of primary liver tumors. Mol. Pharmaceut. 9, 1693\u20131704. https:\/\/doi.org\/10.1021\/mp300028a (2012).","journal-title":"Mol. Pharmaceut"},{"key":"81392_CR36","doi-asserted-by":"publisher","first-page":"857","DOI":"10.22034\/APJCP.2017.18.3.857","volume":"18","author":"S Pongmaneratanakul","year":"2017","unstructured":"Pongmaneratanakul, S., Tanasanvimon, S., Pengsuparp, T. & Areepium, N. Prevalence of CTR1 and ERCC1 polymorphisms and response of biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy. Asian Pac. J. Cancer Prev. 18, 857\u2013861. https:\/\/doi.org\/10.22034\/APJCP.2017.18.3.857 (2017).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"81392_CR37","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.3748\/wjg.v18.i30.3955","volume":"18","author":"C Hahnvajanawong","year":"2012","unstructured":"Hahnvajanawong, C. et al. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J. Gastroentero. 18, 3955\u20133961. https:\/\/doi.org\/10.3748\/wjg.v18.i30.3955 (2012).","journal-title":"World J. Gastroentero"},{"key":"81392_CR38","doi-asserted-by":"crossref","unstructured":"Zeekpudsa, P., Kukongviriyapan, V., Senggunprai, L., Sripa, B. & Prawan, A. Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents. Journal of Experimental & Clinical Cancer Research 33. https:\/\/doi.org\/Artn 1110.1186\/1756-9966-33-11 (2014).","DOI":"10.1186\/1756-9966-33-11"},{"key":"81392_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/hep.24698","volume":"55","author":"N Razumilava","year":"2012","unstructured":"Razumilava, N. et al. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology 55, 465\u2013475. https:\/\/doi.org\/10.1002\/hep.24698 (2012).","journal-title":"Hepatology"},{"key":"81392_CR40","doi-asserted-by":"crossref","unstructured":"Kerdkumthong, K. et al. Proteomics and Bioinformatics Identify Drug-Resistant-Related Genes with Prognostic Potential in Cholangiocarcinoma. Biomolecules 14. https:\/\/doi.org\/ARTN 96910.3390\/biom14080969 (2024).","DOI":"10.3390\/biom14080969"},{"key":"81392_CR41","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s13577-023-01003-4","volume":"37","author":"M Bai","year":"2024","unstructured":"Bai, M. et al. Establishment and characterization of a novel hilar cholangiocarcinoma cell line, CBC3T-1. Hum. Cell. 37, 364\u2013375. https:\/\/doi.org\/10.1007\/s13577-023-01003-4 (2024).","journal-title":"Hum. Cell"},{"key":"81392_CR42","unstructured":"Bailey, M. H. et al. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173, 371-+. (2018). https:\/\/doi.org\/ARTN385.e110.1016\/j.cell.02.060 (2018)."},{"key":"81392_CR43","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein, B. et al. Cancer Genome Landscapes Sci. 339, 1546\u20131558. https:\/\/doi.org\/10.1126\/science.1235122 (2013).","journal-title":"Cancer Genome Landscapes Sci."},{"key":"81392_CR44","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1038\/srep02650","volume":"3","author":"D Tamborero","year":"2013","unstructured":"Tamborero, D. et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci. Rep. 3, 2650. https:\/\/doi.org\/10.1038\/srep02650 (2013).","journal-title":"Sci. Rep."},{"key":"81392_CR45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333\u2013. https:\/\/doi.org\/10.1038\/nature12634 (2013).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81392-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81392-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81392-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:06:10Z","timestamp":1732856770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81392-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["81392"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81392-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the First Hospital of Lanzhou University, Lanzhou, Gansu, China (Approval number: LDYYLL2024-296).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical declarations"}},{"value":"The participant provided written informed consent for the use of her clinical and pathological specimens.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29661"}}